APA (7th ed.) Citation

Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., . . . Rajkumar, S. V. (2025). Daratumumab or active monitoring for high-risk smoldering multiple myeloma. The New England journal of medicine, 392(18), . https://doi.org/10.1056/NEJMoa2409029

Chicago Style (17th ed.) Citation

Dimopoulos, Meletios A., et al. "Daratumumab or Active Monitoring for High-risk Smoldering Multiple Myeloma." The New England Journal of Medicine 392, no. 18 (2025). https://doi.org/10.1056/NEJMoa2409029.

MLA (9th ed.) Citation

Dimopoulos, Meletios A., et al. "Daratumumab or Active Monitoring for High-risk Smoldering Multiple Myeloma." The New England Journal of Medicine, vol. 392, no. 18, 2025, https://doi.org/10.1056/NEJMoa2409029.